Teva Pharma Industries Ltd ADR (TEVA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $51.92B
Last updated: Nov 17, 2026 at 11:06 AM ET
Teva Pharma Industries Ltd ADR (TEVA) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Teva Pharma Industries Ltd ADR reported EPS of $0.83, above the $0.70 estimate. It beat the EPS estimate in each of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 29.2% below the $0.96 reported for the quarter ended Dec 31, 2025.
TEVA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
TEVA Earnings Call
The latest TEVA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, TEVA beat 26, missed 9 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $4.39B, down 2.0% from $4.48B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.83 | $0.70 | $0.60 - $0.89 | +18.57% | Beat | +10.7% | 12 | N/A | Nov 3, 2026 | $4.39B |
| Jun 30, 2026 | $0.64 | $0.05 | -$0.03 - $0.56 | N/A | N/A | -3.0% | 9 | 0 up, 3 down | Jul 29, 2026 | $4.14B |
| Mar 31, 2026 | $0.53 | $0.46 | $0.41 - $0.52 | +15.22% | Beat | +1.9% | 8 | 0 up, 8 down | Apr 29, 2026 | $3.98B |
| Dec 31, 2025 | $0.96 | $0.64 | $0.58 - $0.75 | +50.00% | Beat | +35.2% | 9 | 1 up, 3 down | Jan 28, 2026 | $4.71B |
| Sep 30, 2025 | $0.75 | $0.66 | $0.64 - $0.71 | +13.64% | Beat | +8.7% | 7 | 2 up, 3 down | Nov 5, 2025 | $4.48B |
| Jun 30, 2025 | $0.66 | $0.62 | $0.58 - $0.64 | +6.45% | Beat | +8.2% | 7 | 0 up, 3 down | Jul 30, 2025 | $4.18B |
| Mar 31, 2025 | $0.52 | $0.46 | $0.41 - $0.50 | +13.04% | Beat | +8.3% | 4 | 0 up, 3 down | May 7, 2025 | $3.89B |
| Dec 31, 2024 | $0.71 | $0.70 | $0.67 - $0.75 | +1.43% | Beat | -29.0% | 5 | 0 up, 1 down | Jan 29, 2025 | $4.23B |
| Sep 30, 2024 | $0.69 | $0.66 | $0.63 - $0.68 | +4.55% | Beat | +15.0% | 5 | 2 up, 0 down | Nov 6, 2024 | $4.33B |
| Jun 30, 2024 | $0.61 | $0.55 | $0.51 - $0.58 | +10.91% | Beat | +8.9% | 5 | 0 up, 2 down | Jul 31, 2024 | $4.16B |
| Mar 31, 2024 | $0.48 | $0.51 | $0.47 - $0.54 | -5.88% | Miss | +20.0% | 7 | 1 up, 0 down | May 8, 2024 | $3.82B |
| Dec 31, 2023 | $1.00 | $0.76 | $0.71 - $0.85 | +31.58% | Beat | +40.8% | 8 | 3 up, 0 down | Jan 31, 2024 | $4.46B |
| Sep 30, 2023 | $0.60 | $0.61 | $0.56 - $0.68 | -1.64% | Miss | +1.7% | 8 | 0 up, 0 down | Nov 8, 2023 | $3.85B |
| Jun 30, 2023 | $0.56 | $0.53 | $0.49 - $0.57 | +5.66% | Beat | -17.6% | 7 | 1 up, 0 down | Aug 2, 2023 | $3.88B |
| Mar 31, 2023 | $0.40 | $0.55 | $0.54 - $0.57 | -27.27% | Miss | -27.3% | 8 | 1 up, 0 down | May 10, 2023 | $3.66B |
| Dec 31, 2022 | $0.71 | $0.71 | $0.64 - $0.78 | 0.00% | In line | -7.8% | 10 | 2 up, 0 down | Feb 8, 2023 | $3.88B |
| Sep 30, 2022 | $0.59 | $0.62 | $0.58 - $0.67 | -4.84% | Miss | 0.0% | 9 | 1 up, 0 down | Nov 3, 2022 | $3.60B |
| Jun 30, 2022 | $0.68 | $0.56 | N/A | +21.43% | Beat | +15.3% | N/A | 1 up, 1 down | Jul 26, 2022 | $3.79B |
| Mar 31, 2022 | $0.55 | $0.55 | $0.48 - $0.61 | 0.00% | In line | -12.7% | 13 | 1 up, 0 down | May 3, 2022 | $3.66B |
| Dec 31, 2021 | $0.77 | $0.73 | $0.67 - $0.81 | +5.48% | Beat | +13.2% | 14 | 0 up, 0 down | Feb 9, 2022 | $4.10B |
| Sep 30, 2021 | $0.59 | $0.65 | $0.62 - $0.68 | -9.23% | Miss | +1.7% | 14 | N/A | Oct 27, 2021 | $3.89B |
| Jun 30, 2021 | $0.59 | $0.59 | $0.50 - $0.63 | 0.00% | In line | +7.3% | 16 | N/A | Jul 28, 2021 | $3.91B |
| Mar 31, 2021 | $0.63 | $0.60 | $0.56 - $0.63 | +5.00% | Beat | -17.1% | 17 | N/A | Apr 28, 2021 | $3.98B |
| Dec 31, 2020 | $0.68 | $0.62 | $0.54 - $0.69 | +9.68% | Beat | +9.7% | 19 | N/A | Feb 10, 2021 | $4.45B |
| Sep 30, 2020 | $0.58 | $0.58 | $0.55 - $0.62 | 0.00% | In line | 0.0% | 18 | N/A | Nov 5, 2020 | $3.98B |
| Jun 30, 2020 | $0.55 | $0.53 | $0.50 - $0.60 | +3.77% | Beat | -8.3% | 18 | N/A | Aug 5, 2020 | $3.87B |
| Mar 31, 2020 | $0.76 | $0.59 | $0.51 - $0.64 | +28.81% | Beat | +26.7% | 17 | N/A | May 7, 2020 | $4.36B |
| Dec 31, 2019 | $0.62 | $0.61 | $0.57 - $0.66 | +1.64% | Beat | +17.0% | 19 | N/A | Feb 12, 2020 | $4.47B |
| Sep 30, 2019 | $0.58 | $0.59 | $0.55 - $0.64 | -1.69% | Miss | -14.7% | 19 | N/A | Nov 7, 2019 | $4.26B |
| Jun 30, 2019 | $0.60 | $0.58 | $0.51 - $0.94 | +3.45% | Beat | -23.1% | 20 | N/A | Aug 7, 2019 | $4.34B |
| Mar 31, 2019 | $0.60 | $0.58 | $0.48 - $0.62 | +3.45% | Beat | -36.2% | 20 | N/A | May 2, 2019 | $4.29B |
| Dec 31, 2018 | $0.53 | $0.55 | $0.41 - $0.64 | -3.64% | Miss | -43.0% | 19 | N/A | Feb 13, 2019 | $4.56B |
| Sep 30, 2018 | $0.68 | $0.54 | $0.50 - $0.68 | +25.93% | Beat | -32.0% | 18 | N/A | Nov 1, 2018 | $4.53B |
| Jun 30, 2018 | $0.78 | $0.64 | $0.51 - $0.74 | +21.88% | Beat | -23.5% | 21 | N/A | Aug 2, 2018 | $4.70B |
| Mar 31, 2018 | $0.94 | $0.67 | $0.52 - $0.75 | +40.30% | Beat | -11.3% | 24 | N/A | May 3, 2018 | $5.07B |
| Dec 31, 2017 | $0.93 | $0.76 | $0.70 - $0.93 | +22.37% | Beat | -32.6% | 22 | N/A | Feb 8, 2018 | $5.46B |
| Sep 30, 2017 | $1.00 | $1.03 | $0.94 - $1.19 | -2.91% | Miss | -23.7% | 22 | N/A | Nov 2, 2017 | $5.61B |
| Jun 30, 2017 | $1.02 | $1.06 | $0.92 - $1.17 | -3.77% | Miss | -18.4% | 21 | N/A | Aug 3, 2017 | $5.69B |
| Mar 31, 2017 | $1.06 | $1.03 | N/A | +2.91% | Beat | -11.7% | N/A | N/A | May 11, 2017 | $5.63B |
| Dec 31, 2016 | $1.38 | $1.35 | N/A | +2.22% | Beat | +7.8% | N/A | N/A | Feb 13, 2017 | $6.49B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.89, up 16.1% from the year before. It was $5.14 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.89 | +16.1% |
| Dec 31, 2024 | $2.49 | -2.7% |
| Dec 31, 2023 | $2.56 | N/A |
| Dec 31, 2022 | $2.53 | -1.9% |
| Dec 31, 2021 | $2.58 | N/A |
| Dec 31, 2020 | $2.57 | +7.1% |
| Dec 31, 2019 | $2.40 | -18.1% |
| Dec 31, 2018 | $2.93 | -26.9% |
| Dec 31, 2017 | $4.01 | -22.0% |
| Dec 31, 2016 | $5.14 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 11,134 | 15 | |
| 2026Q2 | Jun 30, 2026 | 6,027 | 14 | |
| 2026Q1 | Mar 31, 2026 | 7,316 | 15 | |
| 2025Q4 | Dec 31, 2025 | 7,297 | 13 | |
| 2025Q3 | Sep 30, 2025 | 8,892 | 13 | |
| 2025Q2 | Jun 30, 2025 | 7,789 | 13 | |
| 2025Q1 | Mar 31, 2025 | 6,779 | 11 | |
| 2024Q4 | Dec 31, 2024 | 5,620 | 13 |
2026Q3 Earnings Call
Opening remarks
Christopher Stevo Head of Investor Relations Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us for our third quarter earnings call. As usual, our materials are posted to our website this morning, so please feel free to see them there. Before I turn the call over to our CEO, Richard Francis, I would like to remind everyone that we will be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, and we undertake no obligation to update those statements subsequently. However, I will now undertake the obligation to give you our CEO, Richard Francis.
Richard Francis CEO Thank you, Chris. Good morning, good afternoon, everybody. Thank you for joining the call. With me today on this call will be Dr. Eric Hughes, Head of Global R&D and Chief Medical Officer, and Eli Kalif, CFO. Moving on to the next slide. As I always do, I start with the pivot to growth strategy and the four pillars. We launched it in 2023, and I am going to give you an update in Q3 on the progress we have made against this strategy. Starting with deliver on our growth engines. You will see that the innovative portfolio continues to perform well. AUSTEDO, AJOVY, and UZEDY are all delivering strong Q3 performance, and our innovative portfolio is up 33%. We are raising full-year guidance across all of these products. Now, the importance of these products can be seen in our financials, and you'll see that our revenue is stronger, our margins and our free cash flow also become stronger. Now looking to the second pillar, step up innovation. You see that we've had eight major milestone readouts this year, but also we've seen some big progress. The approval of UZEDY was a significant moment for Teva as well as the patients suffering from schizophrenia. We also have good progress in the pipeline, and we have FDA fast-track designation for our anti-IL-15 candidate for celiac disease. Looking ahead, we have four additional potential submissions over the next five years. With regard to an announcement we made earlier in the week, emrusolmin, after an independent data monitoring committee met on a prespecified interim futility analysis, we have discontinued the Phase II study. It's worth pointing out there were no safety concerns.
Frequently Asked Questions About TEVA
Did TEVA beat earnings estimates last quarter?
Yes. Teva Pharma Industries Ltd ADR reported EPS of $0.83 for the quarter ended Sep 30, 2026, above the $0.70 estimate, a 18.57% surprise.
What EPS do analysts expect from TEVA next quarter?
The consensus EPS estimate for Teva Pharma Industries Ltd ADR for the quarter ending Dec 31, 2026 is $0.68 from 5 analysts, with estimates from $0.60 to $0.81.
How often does TEVA beat earnings estimates?
Teva Pharma Industries Ltd ADR beat the EPS estimate in each of the 8 most recent quarters that had an estimate, with an average surprise of +15.36%.
TEVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors